HCPCS J9073: Injection, Cyclophosphamide (Dr. Reddy's), 5 mg

HCPCS Level II code J9073 denotes a 5 mg unit of cyclophosphamide (Dr. Reddy's) for parenteral administration. This code identifies the specific drug product and unit dosing used in oncology and immunosuppressive treatment settings and is important for accurate drug billing, inventory control, and clinical documentation at national scale. Consistent coding of cytotoxic agents affects payer reimbursement, patient cost-sharing, and hospital outpatient reporting.

Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. Readers will find a summary of how J9073 is applied across typical infusion center and outpatient clinic encounters, relevant service line context, and common modifier usage (list provided separately). The publication also outlines benchmarking considerations for unitization of multi-dose vials, billing implications for single-use vial wastage, and administrative practices that influence claim adjudication.

The reader will learn practical information about the clinical context for cyclophosphamide dosing, typical sites of service, and how national payers commonly reference HCPCS billing for chemotherapy drugs. Data elements not provided in the input, such as specific payer policy language, reimbursement rates, and ICD-10 pairings, are noted as unavailable for this summary but referenced as areas for further review.

Billing Code Overview

HCPCS Level II code J9073 represents an injection of cyclophosphamide (Dr. Reddy's), 5 mg. This billing code is used for administration of the specified chemotherapeutic agent in measured 5 mg units.

Service type: Chemotherapy drug administration
Typical site of service: Infusion center or outpatient clinic

Clinical Context

A typical patient is an adult with an oncologic or autoimmune indication receiving intravenous cyclophosphamide prepared from a vial labeled as cyclophosphamide (Dr. Reddy's). The service J9073 represents the drug component billed per 5 mg unit. A common scenario is an outpatient oncology infusion visit in an ambulatory infusion center or hospital outpatient infusion suite where a medical oncologist orders cyclophosphamide for treatment of lymphoma, multiple myeloma, metastatic solid tumor, or severe systemic autoimmune disease (for example, systemic lupus erythematosus with organ-threatening involvement).

The clinical workflow: the clinician documents indication and planned dose in the medical record and chemotherapy plan; pharmacy compounds the appropriate intravenous dose using the manufacturer supply; nursing verifies patient identity, pre-medications, and line patency; the infusion nurse administers the drug intravenously with appropriate monitoring for adverse effects; billing submits J9073 units corresponding to the administered milligram dose (converted to 5 mg units) along with applicable infusion administration CPT codes and relevant diagnosis codes that justify medical necessity.

Coding Specifications

Modifier	Description	When to Use
`JW`	Drug discarded/ wastage

Taxonomy Code	Specialty	Notes
`207RG0100X`	Medical Oncology	Primary specialty prescribing and overseeing cyclophosphamide chemotherapy
`208D00000X`	Hematology	Hematologists commonly manage cyclophosphamide for hematologic malignancies
`163WL0200X`	Rheumatology	Prescribes cyclophosphamide for severe systemic autoimmune diseases
`363L00000X`	Infusion Therapy	Infusion nurses and infusion centers provide administration and monitoring
`3336C0001X`	Clinical Pharmacy	Clinical pharmacists compound and verify chemotherapy dosing

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C83.9`	Non-Hodgkin lymphoma, unspecified	Cyclophosphamide is a component of many NHL chemotherapy regimens
`C90.00`	Multiple myeloma not having achieved remission	Cyclophosphamide is used in combination regimens for multiple myeloma
`C79.9`	Secondary malignant neoplasm of unspecified site	Systemic chemotherapy including cyclophosphamide may be used for metastatic disease
`M32.14`	Systemic lupus erythematosus with lupus nephritis	Cyclophosphamide is used for severe, organ-threatening autoimmune disease such as lupus nephritis
`M05.79`	Rheumatoid arthritis with rheumatoid factor, multiple sites (other specified)	Cyclophosphamide may be used for refractory severe rheumatoid disease in select cases

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96413`	Chemotherapy administration, infusion technique; intravenous infusion, up to 1 hour, single or initial substance/drug	Commonly billed for the first hour of cyclophosphamide infusion in the outpatient setting
`96415`	Chemotherapy administration, each additional hour (List separately in addition to code for primary infusion)	Billed for each additional hour of infusion beyond the initial hour when cyclophosphamide infusion duration requires it
`96417`	Chemotherapy administration, intravenous infusion, each additional sequential infusion of a new drug, up to 1 hour	Used when cyclophosphamide is administered as a sequential infusion in combination regimens
`96365`	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	Alternative infusion administration code when not billed as chemotherapy under payer rules
`96374`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential infusion	Used for additional infusion services or when payer requires this code for supportive infusions

OpenPayer

Summary & Overview